TransCode Therapeutics' TTX-MC138 Meets Primary Safety Endpoint in Phase 1a Trial
Bitget2026/10/26 11:32- TransCode Therapeutics presented Phase 1a results for TTX-MC138 in previously treated advanced solid tumors at ESMO Congress 2026 in Madrid.
- The trial met its primary safety endpoint, with no dose-limiting toxicities observed.
- Disease stabilization occurred across the heavily pretreated patient population; some patients experienced extended periods without disease progression.
- TTX-MC138 is currently being evaluated in a Phase 2a trial under the PRE-I-SPY program with Quantum Leap Healthcare Collaborative.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Selloff Sends Berkshire to Its Biggest S&P 500 Lead Since 2010: Can It Last?
Meridian weighs $400 million investment decision for Cabaçal mine
Saudi Arabia's oil production in October surged by 26%, reaching the highest level since the onset of the conflict, while Brent crude has dropped over 20% this month
OPEC's monthly report shows that Saudi Arabia's average daily crude oil production in October rose to 10.56 million barrels, just several hundred thousand barrels lower than the pre-war level in February and slightly above its quoted limit under the OPEC framework. Iraq's daily output in October also reached approximately 4.9 million barrels, a new high since the outbreak of war. Meanwhile, after the UAE exited OPEC and began competing in the market independently, both the UAE and Saudi Arabia recently slashed their official December cargo prices for Asian buyers, intensifying the competitive landscape.
Scorpio hits gold beyond Nevada resource
Crypto prices
More
